CN103159649B - The preparation of sulfamide compound and application thereof - Google Patents
The preparation of sulfamide compound and application thereof Download PDFInfo
- Publication number
- CN103159649B CN103159649B CN201110425746.3A CN201110425746A CN103159649B CN 103159649 B CN103159649 B CN 103159649B CN 201110425746 A CN201110425746 A CN 201110425746A CN 103159649 B CN103159649 B CN 103159649B
- Authority
- CN
- China
- Prior art keywords
- compound
- cell
- sulfamide
- preparation
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Oc1ccccc1 Chemical compound Oc1ccccc1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- ZNYQXLBREYRXGV-UHFFFAOYSA-N CC(C)Cc(cc1)ccc1NC(OC)=O Chemical compound CC(C)Cc(cc1)ccc1NC(OC)=O ZNYQXLBREYRXGV-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to preparation and the application thereof of sulfamide compound, provide in particular sulfamide compound, have the structure shown in following general formula (I), this compounds can suppress the survival and growth of SUM-159, HCC-1954 and MCF-7 cell.
wherein, n=0,1,2 or 3.R is selected from C
2-C
4straight chain or branched paraffin, phenyl, cyclohexyl, o-tolyl, 3-pyridyl, 2-pyridyl ethyl group,
Description
Technical field
The present invention relates to medicinal chemistry art, in particular to sulfamide compound and preparation method thereof and purposes.
Background technology
Mammary cancer (mammarycarcinoma) is the modal a kind of malignant tumour of the mankind is also one of women's major malignant tumor.The malignant tumour overwhelming majority system of breast comes from the epithelium (breast cancer) of mammary gland, and the various non-epithelium (various sarcoma) that minority can be derived from breast occasionally can see blended sarcocarcinoma.The sickness rate of mammary cancer rises year by year, and crowd's morbidity is 23,/10 ten thousand; Account for 7 ~ 10% of the various malignant tumour of women's whole body.
Univ Michigan-Ann Arbor USA researchist MaxS.Wicha in 2010 etc. identify the new effect of a kind of acceptor, CXCR1, are positioned at mammary cancer cancer stem cell surface, under tissue damaged or the stimulation of inflammatory reaction, have the ability exciting cancer stem cell to grow.CXCR1 is the acceptor of interleukin 8 (IL-8), and IL-8 is everlasting in chronic inflammatory diseases and tissue-damaging process and produces.After patient with breast cancer accepts chemotherapy, dead cancer cell can produce IL-8, and this will promote the self-replacation of cancer stem cell.If add relative medicine and block CXCR1 in Breast Cancer Patients Treated process, will effectively help to kill breast carcinoma stem cell.
Reparixin (N-[(R)-2-(4-isobutylphenyl) propionyl]-methanesulfonamide) is a kind of benzyl propionate derivant, interleukin 8 albumen can be suppressed to be combined with acceptor CXCR1, thus block breast carcinoma stem cell FAK/AKT/ beta-catenin path, accurately hit cancer stem cell.Researchist with the experimental mouse of et al. Ke breast cancer cell for object carries out studying rear discovery, accept simultaneously chemotherapy and repertaxin treatment experimental mouse body in cancer stem cell quantity far below the experimental mouse only accepting chemotherapy, further, the probability adding the mouse generation Nasopharyngeal neoplasms of repertaxin treatment also reduces.Interim for suppressing the medicine Reparixin (Repertaxin) of organ naltrindole can kill breast carcinoma stem cell and stop the diffusion of tumour in clinical trial 2 at present.
Up to the present, do not have a kind of medicine fundamentally to suppress or to eliminate breast carcinoma stem cell, reach the effect of thoroughly curing.Therefore, urgently find a kind of better efficacy, toxic side effect is little, the medicine of the treatment mammary cancer of high specificity.
Summary of the invention
The structure of the present invention to Reparixin is optimized, and has newly synthesized a compounds, and replacing the methyl on the sulfoamido in Reparixin with other groups such as phenyl, is sulfamide compound.Pharmacologically active result shows, this compounds can suppress the survival and growth of SUM-159, HCC-1954 and MCF-7 cell.It may be used for prevention or treatment mammary cancer.
The invention provides sulfamide compound, there is general formula (I):
Wherein, R is selected from C
2-C
4straight chain or branched paraffin, phenyl, cyclohexyl, o-tolyl, 3-pyridyl, 2-pyridyl ethyl group,
N=0,1,2 or 3.
In a particular embodiment, described sulfamide compound has general formula (I), wherein R be selected from phenyl,
n=0 and R is selected from methyl, n=2.
The invention provides a kind of method preparing sulfamide compound, comprise the following steps:
Step a: make formula (II) compound
After reacting with condensing agent generation activated carboxylic in aprotic solvent at 0 DEG C and with formula (III) compound
There is condensation reaction production (I) compound in the basic conditions.
Wherein, described aprotic solvent is selected from methylene dichloride, tetrahydrofuran (THF), preferred methylene dichloride, described condensing agent is selected from N, N '-carbonyl dimidazoles (CDI), and described alkali is selected from 1,8-diazabicylo-dicyclo (5,4,0)-7-hendecene (DBU).
Wherein, n=0,1,2 or 3; Formula (III) compound R is selected from C
2-C
4straight chain or branched paraffin, phenyl, cyclohexyl, o-tolyl, 3-pyridyl, 2-pyridyl ethyl group,
The invention provides the method that one prepares general formula (I) sulfamide compound, comprising:
Step a: make formula (II) compound
After reacting with condensing agent generation activated carboxylic in aprotic solvent at 0 DEG C and with formula (III) compound
There is condensation reaction production (I) compound in the basic conditions,
Wherein, described aprotic solvent is selected from methylene dichloride, tetrahydrofuran (THF), preferred methylene dichloride, described condensing agent is selected from N, N '-carbonyl dimidazoles (CDI), and described alkali is selected from 1,8-diazabicylo-dicyclo (5,4,0)-7-hendecene (DBU).
In a particular embodiment, prepare R in general formula (I) be phenyl,
n=0 and R is methyl, n=2, and configuration is respectively: the method for the sulfamide compound of DL, R, S, comprising:
Step a: make formula (II) compound
After reacting with condensing agent generation activated carboxylic in aprotic solvent at 0 DEG C and with formula (III) compound
There is condensation reaction production (I) compound in the basic conditions.
Wherein, described aprotic solvent is selected from methylene dichloride, tetrahydrofuran (THF), preferred methylene dichloride, described condensing agent is selected from N, N '-carbonyl dimidazoles (CDI), and described alkali is selected from 1,8-diazabicylo-dicyclo (5,4,0)-7-hendecene (DBU).
Wherein, the R in formula (III) be phenyl,
n=0 and R is methyl, n=2, and configuration is respectively: DL, R, S.
Present invention also offers described sulfamide compound prevent in preparation or treat the application in the medicine of mammary cancer.This compounds can suppress the survival and growth of SUM-159, HCC-1954 and MCF-7 cell.Especially in general formula (I) R be phenyl,
n=0 or R was methyl, n=2, the sulfamide compound of different configuration, at 72 hours suppression IC to SUM-159, HCC-1954 and MCF-7 cell
50value is respectively
Thus the medicine that this compounds can be mixed with for prevention or treatment mammary cancer.
Sulfamide compound of the present invention can be mixed to form pharmaceutical preparation according to conventional medicine compounding process and pharmaceutical carrier or vehicle (such as pharmaceutically acceptable carrier and vehicle).Can described sulfamide compound be blended in any conventional oral dosage form as activeconstituents, described oral dosage form comprises tablet, capsule and liquid preparation (such as elixir and suspensoid), wherein contains the material of toner, correctives, stablizer and taste masking.For mixing oral dosage form, described sulfamide compound can mix with various conventional tablet material (such as starch, calcium carbonate, lactose, sucrose and Si Liaodengji dicalcium phosphate feed grade) to help compressing tablet as activeconstituents and incapsulate.Can dissolve in described sulfamide compound pharmaceutically acceptable sterile liquid carrier such as sterilized water, sterile organic solvent or both mixtures or suspendible.Liquid vehicle can be the carrier of applicable injection, such as physiological saline, propylene glycol or Aqueous Solutions of Polyethylene Glycol.In other cases, can also micronized activeconstituents be dispersed in the aqueous solution of starch or Xylo-Mucine or be dispersed in suitable oil (such as peanut oil) and obtain.Liquid pharmaceutical formulation (referring to sterile solution or suspensoid) may be used for intravenous injection, intramuscular injection, peritoneal injection or subcutaneous injection.
Present invention also offers a kind of pharmaceutical composition, this pharmaceutical composition comprises the of the present invention sulfamide compound of at least one as activeconstituents.In addition, described pharmaceutical composition can also comprise that one or more are inorganic or organic, the pharmaceutically acceptable carrier of solid or liquid or vehicle.Term " pharmaceutically acceptable " refers to and when being administered to animal such as Mammals (such as the mankind), physiology can to tolerate and usually can not produce additive or the composition of irritated or similar untoward reaction (such as dizzy etc.).Pharmaceutical carrier and vehicle can include but not limited to thinner, such as lactose, glucose, seminose and/or glycerine; Lubricant; Polyoxyethylene glycol; Tackiness agent, such as magnesium aluminum silicate, starch, gelatin, methylcellulose gum, Xylo-Mucine and/or polyvinylpyrrolidone; Further, if necessary, also comprise disintegrating agent, such as starch, agar, Lalgine or its salt are as sodium alginate; And/or sorbent material, tinting material, sanitas, stablizer, correctives and sweeting agent.
Embodiment
Be further described with feature to various aspects of the present invention below.
Shortenings used herein is generally well-known to those skilled in the art, or can be understandable according to rudimentary knowledge.
The starting raw material adopted in the preparation of the compounds of this invention is known, that can prepare according to currently known methods or commercially available acquisition.
The invention still further relates to new intermediate and/or starting raw material.Particularly preferably with those the identical or similar reaction conditionss mentioned in embodiment and new intermediate.
Intermediate and end product can carry out aftertreatment and/or purifying according to conventional methods, and described ordinary method comprises and regulates pH, extraction, filtration, drying, concentrated, chromatography, grinding, crystallization etc.
In addition, the compounds of this invention can also be prepared by the alternative of various method known in the art or methods described herein.
The following example only for illustrating the present invention, limits the invention never in any form.
The preparation of embodiment 1 (S)-2-(4-isobutyl phenenyl)-N-(benzenesulfonyl) propionic acid amide
Step 1
Get 50ml round-bottomed flask, by CDI (0.41g, inside dichloromethane solution 2.52mmol) adding the drying of (S)-2-(4-isobutyl phenenyl) propionic acid (0.52g, 2.52mmol) to, mixing solutions stirs 2 hours at 0-5 DEG C.Stirred at ambient temperature 6 hours after adding benzsulfamide (0.39g, 2.52mmol) and DBU (0.3ml), TLC follows the tracks of reaction, after reaction terminates.Organic phase NaH
2pO
4(2*5ml), saturated aqueous common salt (2*5ml) is washed.With anhydrous sodium sulfate drying, solvent is removed.(sherwood oil: ethyl acetate=5: 1) obtain target compound (0.70g productive rate 80%) is separated with silica gel column chromatography.
The MS:[M+H of this compound]
+346.14;
1h-NMR (400MHz, CDCl
3) δ 7.95 (d, 2H), 7.80 (s, 1HCONH), 7.64 (t, 1H), 7.55 (t, 2H), 7.10 (d, 2H), 6.93 (d, 2H), 3.58 (q, 1H), 2.50 (d, 2H), 1.92 (m, 1H), 1.35 (d, 3H), 0.95 (d, 6H).
The preparation of embodiment 2 (R)-2-(4-isobutyl phenenyl)-N-(benzenesulfonyl) propionic acid amide
Step 1
Get 50ml round-bottomed flask, by CDI (0.41g, inside dichloromethane solution 2.52mmol) adding the drying of (R)-2-(4-isobutyl phenenyl) propionic acid (0.52g, 2.52mmol) to, mixing solutions stirs 2 hours at 0-5 DEG C.Stirred at ambient temperature 6 hours after adding benzsulfamide (0.39g, 2.52mmol) and DBU (0.3ml), TLC follows the tracks of reaction, after reaction terminates.Organic phase NaH
2pO
4(2*5ml), saturated aqueous common salt (2*5ml) is washed.With anhydrous sodium sulfate drying, solvent is removed.(sherwood oil: ethyl acetate=5: 1) obtain target compound (0.70g productive rate 80%) is separated with silica gel column chromatography.
The MS:[M+H of this compound]
+346.14;
1h-NMR (400MHz, CDCl
3) δ 7.95 (d, 2H), 7.80 (s, 1HCONH), 7.64 (t, 1H), 7.55 (t, 2H), 7.10 (d, 2H), 6.93 (d, 2H), 3.58 (q, 1H), 2.50 (d, 2H), 1.92 (m, 1H), 1.35 (d, 3H), 0.95 (d, 6H).
The preparation of embodiment 32-(4-isobutyl phenenyl)-N-(benzenesulfonyl) propionic acid amide
Step 1
Get 50ml round-bottomed flask, inside dichloromethane solution CDI (0.41g, 2.52mmol) being added to the drying of 2-(4-isobutyl phenenyl) propionic acid (0.52g, 2.52mmol), mixing solutions stirs 2 hours at 0-5 DEG C.Stirred at ambient temperature 6 hours after adding benzsulfamide (0.39g, 2.52mmol) and DBU (0.3ml), TLC follows the tracks of reaction, after reaction terminates.Organic phase NaH
2pO
4(2*5ml), saturated aqueous common salt (2*5ml) is washed.With anhydrous sodium sulfate drying, solvent is removed.Be separated (=5: 1) with silica gel column chromatography and obtain target compound (0.62g productive rate 79%).
The MS:[M+H of this compound]
+346.14;
1h-NMR (400MHz, CDCl
3) δ 7.95 (d, 2H), 7.80 (s, 1HCONH), 7.64 (t, 1H), 7.55 (t, 2H), 7.10 (d, 2H), 6.93 (d, 2H), 3.58 (q, 1H), 2.50 (d, 2H), 1.92 (m, 1H), 1.35 (d, 3H), 0.95 (d, 6H).
The preparation of embodiment 4N-((4-hydroxy phenyl) alkylsulfonyl)-2-(4-isobutyl phenenyl) propionic acid amide
Experimental procedure, as shown in example 1, adds 4-hydroxyphenyl sulphonamide (0.44g, 2.52mmol), and silica gel column chromatography is separated (sherwood oil: ethyl acetate=2: 1) obtain target compound (0.71g, productive rate 78%).
The MS:[M+H of this compound]
+362.26;
1h-NMR (400Hz, CDCl
3) δ 7.85 (d, 2H), 7.74 (s, 1HCONH), 7.12 (t, 2H), 7.0 (d, 2H), 6.89 (d, 2H), 5.96 (s, 1HOH), 3.54 (q, 1H), 2.48 (d, 2H), 1.90 (m, 1H), 1.42 (d, 3H), 0.95 (d, 6H).
The preparation of embodiment 5R-N-((4-hydroxy phenyl) alkylsulfonyl)-2-(4-isobutyl phenenyl) propionic acid amide
Experimental procedure, as shown in example 1, adds 4-hydroxyphenyl sulphonamide (0.44g, 2.52mmol), and silica gel column chromatography is separated (sherwood oil: ethyl acetate=2: 1) obtain target compound (0.71g, productive rate 78%).
The MS:[M+H of this compound]
+362.26;
1h-NMR (400Hz, CDCl
3) δ 7.85 (d, 2H), 7.74 (s, 1HCONH), 7.12 (t, 2H), 7.0 (d, 2H), 6.89 (d, 2H), 5.96 (s, 1HOH), 3.54 (q, 1H), 2.48 (d, 2H), 1.90 (m, 1H), 1.42 (d, 3H), 0.95 (d, 6H).
The preparation of embodiment 6S-N-((4-hydroxy phenyl) alkylsulfonyl)-2-(4-isobutyl phenenyl) propionic acid amide
Experimental procedure, as shown in example 1, adds 4-hydroxyphenyl sulphonamide (0.44g2.52mmol), and silica gel column chromatography is separated (sherwood oil: ethyl acetate=2: 1) obtain target compound (0.71g, productive rate 78%).
The MS:[M+H of this compound]
+362.26;
1h-NMR (400Hz, CDCl
3) δ 7.85 (d, 2H), 7.74 (s, 1HCONH), 7.12 (t, 2H), 7.0 (d, 2H), 6.89 (d, 2H), 5.96 (s, 1HOH), 3.54 (q, 1H), 2.48 (d, 2H), 1.90 (m, 1H), 1.42 (d, 3H), 0.95 (d, 6H).
The preparation of embodiment 72-(4-isobutyl phenenyl)-N-(2-(methylsulfonyl) ethyl) propionic acid amide
Experimental procedure, as shown in example 1, adds Toluidrin ethamine (0.31g, 2.52mmol), and silica gel column chromatography is separated (sherwood oil: ethyl acetate=2: 1) obtain target compound (0.70g, productive rate 77%).
The MS:[M+H of this compound]
+312.31;
1h-NMR (400Hz, CDCl
3) δ 7.19 (d, 2H), 7.15 (d, 2H), 6.06 (s, 1HCONH), 3.72 (q, 2H), 3.55 (q, 1H), 3.19 (t, 2H), 2.82 (s, 3H), 2.47 (d, 2H), 1.86 (m, 1H), 1.53 (d, 3H), 0.92 (d, 6H).
The preparation of embodiment 8S-2-(4-isobutyl phenenyl)-N-(2-(methylsulfonyl) ethyl) propionic acid amide
Experimental procedure, as shown in example 1, adds Toluidrin ethamine (0.31g, 2.52mmol), and silica gel column chromatography is separated (sherwood oil: ethyl acetate=2: 1) obtain target compound (0.70g, productive rate 77%).
The MS:[M+H of this compound]
+312.31;
1h-NMR (400Hz, CDCl
3) δ 7.19 (d, 2H), 7.15 (d, 2H), 6.06 (s, 1HCONH), 3.72 (q, 2H), 3.55 (q, 1H), 3.19 (t, 2H), 2.82 (s, 3H), 2.47 (d, 2H), 1.86 (m, 1H), 1.53 (d, 3H), 0.92 (d, 6H).
The preparation of embodiment 9R-2-(4-isobutyl phenenyl)-N-(2-(methylsulfonyl) ethyl) propionic acid amide
Experimental procedure, as shown in example 1, adds Toluidrin ethamine (0.31g, 2.52mmol), and silica gel column chromatography is separated (sherwood oil: ethyl acetate=2: 1) obtain target compound (0.50g, productive rate 64%).
The MS:[M+H of this compound]
+312.31;
1h-NMR (400Hz, CDCl
3) δ 7.19 (d, 2H), 7.15 (d, 2H), 6.06 (s, 1HCONH), 3.72 (q, 2H), 3.55 (q, 1H), 3.19 (t, 2H), 2.82 (s, 3H), 2.47 (d, 2H), 1.86 (m, 1H), 1.53 (d, 3H), 0.92 (d, 6H).
pharmacologically active part
The present invention adopts MTT colorimetric method for determining cytoactive.
MTT colorimetry is a kind of method detecting cell survival and growth.Its Cleaning Principle is that the succinodehydrogenase in viable cell plastosome can make exogenous MTT be reduced to water-insoluble bluish voilet crystallization first a ceremonial jade-ladle, used in libation (Formazan) and be deposited in cell, and dead cell is without this function.First a ceremonial jade-ladle, used in libation in dimethyl sulfoxide (DMSO) (DMSO) energy dissolved cell, measures its absorbance value with enzyme-linked immunosorbent assay instrument at 490nm wavelength place, can indirectly reflect viable cell quantity.Within the scope of certain cell count, the amount that the crystallization of first a ceremonial jade-ladle, used in libation is formed is directly proportional to cell count.
MTT full name is 3-(4,5)-dimethylthiahiazo (-z-y1)-3,5-di-phenytetrazoliumromide, chemistry 3-(4 by name, 5-dimethylthiazole-2)-2,5-diphenyltetrazolium bromide bromine salt, commodity are called tetrazolium bromide, are a kind of dyestuffs of yellow color.
MTT powder is bought in Sigma company, and during use, phosphoric acid buffer (PBS) is mixed with the solution that concentration is 5mg/ml, with 0.22 μm of membrane filtration to remove the bacterium in solution, then keeps in Dark Place at 4 DEG C.
MTT colorimetric method for determining cytoactive comprises several step (for the testing method of cell SUM-159, the testing method of cell HCC-1954 with MCF-7 is consistent with the method for SUM-159) below:
Step 1): dosing spreads 96 orifice plates with SUM-159, HCC-1954 and MCF-7 cell (purchased from gold amethyst bio tech ltd, Beijing) noon before that day.Collect SUM-159, HCC-1954 and MCF-7 cell of logarithmic phase, after viable count, adjust cell concn to 2.5 × 10
4cells/mL.Inoculating cell in 96 orifice plates, every hole adds 100 μ L cell suspension bed boards, and final cell to be measured is 2500cells/ hole.Surrounding marginal pore not inoculating cell, only add 100 μ L cell culture mediums (cell culture medium used in this experiment is modified form RPMI-1640 (Hyclone) basic medium, adds the foetal calf serum (Hyclone) of 10%).5%CO
2, 37 DEG C of overnight incubation, to make cell fully adherent.
Step 2): dosing in morning next day.First dilute medicine, prepare corresponding drug concentration gradient.Add the medicine of the corresponding concentration of 100 μ L in the cell of 96 orifice plates completed to the day before yesterday, be provided with 9 concentration gradients in this experiment, system Chinese traditional medicine final concentration gradient is: 30 μMs, 25 μMs, 20 μMs, 15 μMs, 10 μMs, 5 μMs, 3 μMs, 1 μM, 0.5 μM.Each concentration arranges 5 repetitions.The hole simultaneously arranging not dosing only inoculating cell is control group, and control group not dosing, adds the cell culture medium of 100 μ L; The hole that non-inoculating cell only adds substratum is set and is set to blank well, also add 100 μ L cell culture mediums.5%CO
2, 37 DEG C of incubators hatch 72 hours.
Step 3): after 72 hours, every hole adds 20 μ LMTT solution (5mg/ml, MTT) again, continues cultivation 4 hours.If medicine and MTT can react, can first centrifugal after discard nutrient solution, carefully with PBS rinse 2-3 all over after, then add the nutrient solution containing MTT.
Step 4): stop after 4 hours cultivating, carefully suck liquid in hole.Every hole adds 150 μ L dimethyl sulfoxide (DMSO), and 37 DEG C of incubators hatch 10 minutes.Enzyme-linked immunosorbent assay instrument MULTISKANFC (Thermoscientific) is adopted to measure the light absorption value in each hole, 490nm place, using blank well as zeroing hole during measurement.
Step 5): processing data.First following formulae discovery inhibiting rate is adopted:
Inhibiting rate=1-dosing group OD value/control group OD value
Then with LogC (drug level logarithm) for X-coordinate, inhibiting rate is ordinate zou, carry out probit weighted regression method (Bliss method) with data processing software SPSS software (IBM Corporation) and carry out data processing, mapping, obtains IC50 value.
According to above-mentioned testing method, record embodiment 1-9 compound at 72 hours suppression IC to SUM-159, HCC-1954 and MCF-7 cell
50value is respectively
| SUM-159 | HCC-1954 | MCF-7 | |
| Embodiment 1 | 2.595μM | 23.224μM | 13.255μM |
| Embodiment 2 | 22.843μM | 56.242μM | 24.255μM |
| Embodiment 3 | 14.635μM | 52.544μM | 19.235μM |
| Embodiment 4 | 4.678μM | 11.654μM | 21.253μM |
| Embodiment 5 | 14.650μM | 25.242μM | 51.225μM |
| Embodiment 6 | 6.234μM | 13.242μM | 45.955μM |
| Embodiment 7 | 8.355μM | 16.654μM | 45.235μM |
| Embodiment 8 | 15.447μM | 45.242μM | 78.225μM |
| Embodiment 9 | 16.667μM | 27.542μM | 62.435μM |
According to foregoing, the survival and growth that the compounds of this invention effectively can suppress SUM159, HCC-1954 cell can be understood, slightly poor to the survival and growth restraining effect of MCF-7 cell.The compounds of this invention may be used for prevention or treatment mammary cancer, is expected to substitute the Reparixin easily producing resistance.
In order to clear and understandable object, explanation and embodiment describe in detail foregoing invention by way of example.Can carry out changing and revising in the scope of subsidiary claim, this be clearly to one skilled in the art.Therefore, the specification sheets being appreciated that above be intended to for illustration of instead of for restriction.Therefore, scope of the present invention should not determined with reference to above-mentioned specification sheets, and should determine with reference to the determined four corner of doctrine of equivalents that claims and these claims are enjoyed below.
Claims (6)
1. sulfamide compound, has general formula (I):
Wherein, n=1,2 or 3;
R is selected from phenyl,
2. sulfamide compound according to claim 1, wherein R methyl substitutes, n=2.
3. prepare the method for sulfamide compound according to claim 1, comprise the following steps:
A: make formula (II) compound
After reacting with condensing agent generation activated carboxylic in aprotic solvent at 0 DEG C and with formula (III) compound
There is condensation reaction production (I) compound in the basic conditions,
Wherein, n=1,2 or 3; In formula (III), R is selected from phenyl,
4. prepare the method for sulfamide compound according to claim 2, comprising:
Step a: make formula (II) compound
After reacting with condensing agent generation activated carboxylic in aprotic solvent at 0 DEG C and with formula (III) compound
There is condensation reaction production (I) compound in the basic conditions,
Wherein R is selected from methyl, n=2.
5. sulfamide compound according to claim 1 prevents in preparation or treats the application in the medicine of mammary cancer.
6. a pharmaceutical composition, this pharmaceutical composition comprises the according to claim 1 sulfamide compound of at least one as activeconstituents.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110425746.3A CN103159649B (en) | 2011-12-19 | 2011-12-19 | The preparation of sulfamide compound and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110425746.3A CN103159649B (en) | 2011-12-19 | 2011-12-19 | The preparation of sulfamide compound and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103159649A CN103159649A (en) | 2013-06-19 |
| CN103159649B true CN103159649B (en) | 2016-03-09 |
Family
ID=48583218
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110425746.3A Expired - Fee Related CN103159649B (en) | 2011-12-19 | 2011-12-19 | The preparation of sulfamide compound and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103159649B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017184604A1 (en) | 2016-04-18 | 2017-10-26 | Ifm Therapeutics, Inc | Compounds and compositions for treating conditions associated with nlrp activity |
| US20230210834A1 (en) * | 2019-08-26 | 2023-07-06 | National University Corporation Okayama University | Rna methyltransferase inhibitor, screening method therefor, anti-cancer agent efficacy assessment marker, and kit for effectively predicting ftsj1 inhibitor |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1514824A (en) * | 2001-06-06 | 2004-07-21 | Benzoylsulfonamides and sulfonylbenzamidines for use as antitumour agents | |
| WO2005090295A2 (en) * | 2004-03-23 | 2005-09-29 | Dompe' Pha.R.Ma S.P.A. | 2-phenylpropionic acid derivatives and pharmaceutical compositions containing them |
| CN101857572A (en) * | 2010-06-08 | 2010-10-13 | 东南大学 | 4-aromatic amino pyrimidine derivative and application thereof |
| CN102272599A (en) * | 2008-11-11 | 2011-12-07 | 密执安大学评议会 | Anti-cxcr1 compositions and methods |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1303249B1 (en) * | 1998-10-23 | 2000-11-06 | Dompe Spa | SOME N- (2-ARYL-PROPIONYL) -SULPHONAMIDS AND PHARMACEUTICAL PREPARATIONS THAT CONTAIN THEM. |
-
2011
- 2011-12-19 CN CN201110425746.3A patent/CN103159649B/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1514824A (en) * | 2001-06-06 | 2004-07-21 | Benzoylsulfonamides and sulfonylbenzamidines for use as antitumour agents | |
| WO2005090295A2 (en) * | 2004-03-23 | 2005-09-29 | Dompe' Pha.R.Ma S.P.A. | 2-phenylpropionic acid derivatives and pharmaceutical compositions containing them |
| CN102272599A (en) * | 2008-11-11 | 2011-12-07 | 密执安大学评议会 | Anti-cxcr1 compositions and methods |
| CN101857572A (en) * | 2010-06-08 | 2010-10-13 | 东南大学 | 4-aromatic amino pyrimidine derivative and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103159649A (en) | 2013-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210047303A1 (en) | Alkyne substituted quinazoline compound and methods of use | |
| CN101475594B (en) | Liver targeted antivirus precursor medicament annular phosphoester and use thereof | |
| CN108440583A (en) | A kind of new boronic acid derivatives and its pharmaceutical composition | |
| CN104003925B (en) | Oxindole compounds or derivatives thereof and uses thereof | |
| CN109364026A (en) | The preparation and application of the breast cancer targeting lipids material of biotin modification | |
| CN102666530B (en) | Imatinib dichloroacetate and anti-cancer agent comprising the same | |
| CN103648500A (en) | Methods and use of bifunctional enzyme-building clamp-shaped molecules | |
| CN103159649B (en) | The preparation of sulfamide compound and application thereof | |
| CN1434715A (en) | Pharmaceutical compositions | |
| CN103319402B (en) | Diphenyl thiourea derivatives, preparation method and applications thereof | |
| CN1944448A (en) | Puerarin derivative and its medicinal use | |
| CN103172547A (en) | Preparation and application of sulfamide derivative | |
| CN103159652B (en) | The preparation of sulfinyl amine compounds and application thereof | |
| CN103159650B (en) | The preparation of aromatic heterocycle sulfamide compound and application thereof | |
| CN104892580A (en) | Novel benzimidazole-pyrilamine derivative and application thereof | |
| CN102746212B (en) | Beta-elemene indole derivative, preparation and application thereof | |
| CN103159741A (en) | Preparation and application of novel tyrosine kinase inhibitor | |
| CN103159739A (en) | 1, 4-disubstituted-1, 2, 3-triazole compounds and preparation method thereof | |
| CN104098526B (en) | Amide phenyl-1,3,4-oxadiazole compounds and its preparation method and application | |
| CN101597276B (en) | Propylidene derivative of N-(Alpha, Beta-dimercapto-Beta-carboxyl propionyl)-amino acid and synthetic method and application thereof | |
| CN103172548A (en) | Preparation method and application of methanesulfonamide compound | |
| CN111138449A (en) | Preparation of dual-targeting ERK1 and ERK5 inhibitors and antitumor application thereof | |
| WO2019056375A1 (en) | Acid-sensitive gefitinib axially substituted silicon phthalocyanine complex and preparation method therefor and medical use thereof | |
| CN103172578A (en) | 4-ring end substituted 2-1,2,3-triazole phenylamines compound, preparation and purpose | |
| CN103130774A (en) | Compound with tyrosine kinase inhibition effect and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160309 Termination date: 20211219 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |